5 results about "Lipid profile" patented technology

A personalized supplement formulation system integrates biological data, structured qualitative feedback, and machine learning algorithms to generate individualized nutritional protocols. The system receives biological inputs such as genetic single nucleotide polymorphism (SNP) data, blood biomarkers (e.g., ferritin, vitamin D, B12), lipid profiles, and urinary metabolites. A digital user profile is created by organizing these inputs and calculating derived indices relevant to supplementation. Structured qualitative feedback, including dietary restrictions, perceived wellness, and training goals, is normalized and processed alongside the biological data. A trained machine learning engine analyzes combined inputs to output a tailored supplement formulation specifying ingredient selection, dosage, delivery format, and timing. Instructions are transmitted to a manufacturing system capable of producing the custom formulation. The system supports periodic re-evaluation and iteration based on new biological samples or user-reported feedback, enabling dynamic personalization over time and improving efficacy, compliance, and outcome tracking in athletic and wellness domains.

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The invention discloses bacteroides vulgaris AF107-22 and an application of the bacteroides vulgaris AF107-22. The strain is preserved in Guangdong Microbial Culture Collection Center on January 30, 2026, and the preservation number is GDMCC No: 67775. Animal experiments prove that the strain can effectively colonize and remodel the intestinal flora homeostasis of high fat diet induced metabolic syndrome mice, and specifically promote the biosynthesis of intestinal endogenous spermidine. Based on the core function, the strain can significantly improve metabolic disorders of model mice, including reducing body weight, improving insulin resistance and sugar tolerance, regulating serum lipid mass spectrum and alleviating liver fatty degeneration and inflammatory injury. The invention protects the bacterial strain, a composition thereof, and application of the bacterial strain in preparation of products such as drugs and health foods for promoting synthesis of endogenous spermidine or improving metabolic syndrome.

The present invention relates to a clinical decision support system comprising a processing unit in communication with a memory. The processing unit is configured to receive and process clinical data associated with a patient, which comprises medical records, biometric or physiological data, and / or currently prescribed medication information. The system computes personalized target lipid profile ranges based on the clinical data and medical guidelines stored in the memory. Preferably, the system receives pharmacogenetic analysis data and measured lipid profile values from patient blood tests. The processing unit compares the measured lipid values with the personalized target ranges and, if deviations are found, computes a list of potential medication treatments. This list is sorted based on the estimated effects of each treatment on the lipid profile values, the different between measured and objective lipid profile values, on the clinical data and / or on the pharmacogenetic analysis. The system further outputs data related to the personalized lipid ranges, the comparison of measured values, and / or the suggested medication treatments.

This application belongs to the field of cell biology and tissue engineering technology, specifically relating to a method and composition for in vitro regeneration of meibomian gland organoids. This application identifies Prom1⁺ cells, bipotent progenitor cells capable of maintaining meibomian gland homeostasis, at the acinar-duct junction. This application establishes a three-stage organoid culture system that enables the expansion and culture of meibomian gland-derived somatic cells containing Prom1⁺ cells. By precisely controlling signal transduction at specific stages, the developmental trajectory of meibomian gland tissue is accurately reproduced, generating functional organoids. These organoids exhibit high transcriptional fidelity to natural tissues and significantly retain the natural lipid profile. The method of this application is applicable to culturing starting cell populations containing Prom1⁺ cells to obtain functional meibomian gland organoids, providing a high-fidelity model for studying meibomian gland biology, simulating meibomian gland degeneration (MGD), and developing cell-based DED therapies.